Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.62 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 10/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25256638 | 1.00 | SYK (0.62) | SYKCTRB1CASP1CTSKATM | |
| SCHEMBL6685929 | 0.90 | SYK (0.59) | SYKCTRB1CASP1CTSKATM | |
| SCHEMBL6685926 | 0.90 | SYK (0.59) | SYKCTRB1CASP1CTSKATM | |
| SCHEMBL7496788 | 0.90 | SYK (0.62) | SYKCTRB1CASP1CTSKATM | |
| SCHEMBL7360205 | 0.90 | CTRB1 (0.62) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL12849405 | 0.90 | SYK (0.72) | SYKCTRB1CASP1CTSKATM | |
| SCHEMBL7360200 | 0.90 | CTRB1 (0.62) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL5197783 | 0.90 | SYK (0.62) | SYKCTRB1CASP1CTSKATM | |
| Biphenyl SCHEMBL5686500 | 0.89 | SYK (0.52) | SYKCTRB1CASP1CTSLITGB3 | |
| SCHEMBL19401966 | 0.89 | SYK (0.58) | SYKCTRB1CASP1CTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| EP-4463444-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023131690-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | SYK 2790/4885CTRB1 2529/4885CASP1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.